Fulltext

Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand

Boonlue T 1 , Subongkot S 1 , Dilokthornsakul P 2 , Kongsakon R 3 , Pattanaprateep O 4 , Suanchang O 5 Show all authors , Chaiyakunapruk N 6

Affiliations 

  • 1 Clinical Pharmacy Division, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand; The College of Pharmacotherapy of Thailand, Nonthaburi, Thailand
  • 2 Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; Center for Pharmaceutical Outcomes Research, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA
  • 3 Department of Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 4 Department of Health Informatics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 5 Department of Pharmacy, Somdet Chaopraya Institute of Psychiatry, Bangkok, Thailand
  • 6 Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; School of Population Health, University of Queensland, Brisbane, Australia; School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA
Clinicoecon Outcomes Res, 2016;8:127-36.
PMID: 27199568 DOI: 10.2147/CEOR.S97300

Abstract

Several clinical practice guidelines suggest using atypical over typical antipsychotics in patients diagnosed with schizophrenia. Nevertheless, cost-containment policy urged restricting usage of atypical antipsychotics and switching from atypical to typical antipsychotics.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications